High Growth Tech Stocks In South Korea To Watch

The South Korea stock market turned lower again on Thursday, one day after ending a three-day slide, with the KOSPI now resting just above the 2,660-point plateau. Amidst this fluctuating market environment and ahead of key inflation data, investors are keenly observing high growth tech stocks that have shown resilience and potential for robust performance.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
Seojin SystemLtd	33.61%	52.05%	★★★★★★
IMLtd	21.80%	111.43%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
NEXON Games	31.70%	66.31%	★★★★★★
Devsisters	25.46%	63.02%	★★★★★★
Park Systems	23.49%	35.59%	★★★★★★
UTI	114.97%	134.61%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★

Click here to see the full list of 49 stocks from our KRX High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a biotechnology company, specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with a market cap of ₩16.95 billion.

Operations: ALTEOGEN Inc. generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million. The company focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

ALTEOGEN's recent MFDS approval for Tergase® highlights its innovative Hybrozyme™ Technology, offering over 99% purity and lower immunogenicity compared to animal-derived alternatives. This approval transitions the company into a commercial-stage entity, with revenue growth forecasted at 64.2% annually, outpacing the Korean market's 10.8%. Despite current unprofitability, earnings are projected to grow by 99.46% per year, aiming for profitability within three years. R&D expenses have been significant but crucial in achieving these milestones.

• Dive into the specifics of ALTEOGEN here with our thorough health report.

• Learn about ALTEOGEN's historical performance.

ABL Bio (KOSDAQ:A298380)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases, with a market cap of ₩1.66 trillion.

Operations: ABL Bio generates revenue primarily from its biotechnology startup segment, amounting to ₩32.95 billion. The company's focus is on developing therapeutic drugs for specific medical fields.

ABL Bio's recent private placement raised KRW 140B, reflecting robust investor confidence in its innovative biopharmaceutical solutions. The company's revenue is forecast to grow at an impressive 33.5% annually, significantly outpacing the Korean market's 10.8%. Despite current unprofitability, earnings are projected to surge by 93.9% per year over the next three years, driven by substantial R&D investments crucial for breakthroughs in antibody-drug conjugates and bispecific antibodies.

• Take a closer look at ABL Bio's potential here in our health report.

• Review our historical performance report to gain insights into ABL Bio's's past performance.

HYBE (KOSE:A352820)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: HYBE Co., Ltd. engages in music production, publishing, and artist development and management businesses with a market cap of ₩7.68 billion.

Operations: HYBE Co., Ltd. generates revenue primarily from music production, publishing, and artist development and management, with significant contributions from its Label (₩1.28 billion) and Solution (₩1.24 billion) segments. The Platform segment also adds to the revenue with ₩361 million.

HYBE's earnings are forecast to grow at an impressive 42.5% annually, significantly outpacing the Korean market's 29.1%. Despite a substantial one-off loss of ₩189.4B impacting recent financial results, revenue is projected to increase by 14.1% per year, faster than the market average of 10.8%. The company has also announced a share repurchase program for up to 150,000 shares aimed at stock price stabilization, reflecting confidence in future performance and shareholder value enhancement.

• Delve into the full analysis health report here for a deeper understanding of HYBE.

• Evaluate HYBE's historical performance by accessing our past performance report.

Turning Ideas Into Actions

• Reveal the 49 hidden gems among our KRX High Growth Tech and AI Stocks screener with a single click here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com